CD39/CD73 Adenosine Pathway Pipeline — PatSnap Eureka
CD39/CD73 Adenosine Pathway Pipeline in Solid Tumor Immunotherapy Resistance
The CD39/CD73/adenosine axis has emerged as a critical immunometabolic checkpoint driving immune evasion and resistance to PD-1/PD-L1 and CTLA-4 blockade. Explore the full therapeutic pipeline—from anti-CD73 antibodies to engineered CAR-NK cells—synthesized from patent filings and academic literature spanning 2012–2023.
Adenosine Accumulation: The Dominant Immunosuppressive Mechanism in the TME
Retrieved results consistently identify adenosine accumulation within the tumor microenvironment (TME) as a dominant immunosuppressive mechanism limiting the efficacy of existing immune checkpoint therapies. The pathway proceeds through sequential enzymatic hydrolysis: extracellular ATP is catabolized first to ADP and AMP by CD39 (ENTPD1/NTPDase1), then to immunosuppressive adenosine by CD73 (NT5E/ecto-5′-nucleotidase). Adenosine signals through G protein–coupled receptors—primarily A2AR and, to a lesser extent, A2BR—on immune effector cells including CD8+ T cells, NK cells, and myeloid populations, potently dampening antitumor responses.
Several biological amplifiers drive this pathway: tumor hypoxia drives HIF-1α-dependent upregulation of both CD39 and CD73; high cell turnover releases large quantities of ATP substrate; and regulatory T cells (Tregs) that co-express CD39 and PD-1 are enriched in solid tumor infiltrates. According to research published by the National Institutes of Health, immunometabolic checkpoints like the adenosine axis represent a rapidly expanding therapeutic frontier in oncology.
An alternative, CD39-independent adenosinergic axis driven by CD38, CD203a, and CD73 is capable of generating extracellular adenosine from NAD+ in human T lymphocytes and melanoma cells, representing a critical resistance node for CD39-targeted therapies. Solid tumor types addressed in the dataset include NSCLC, PDAC, colorectal cancer, ovarian cancer, gastric cancer, glioblastoma, melanoma, HNSCC, and multiple myeloma.
The World Health Organization estimates cancer as a leading cause of global mortality, underscoring the urgent need for next-generation immunotherapy approaches that address resistance mechanisms like the adenosine pathway. PatSnap's life sciences intelligence platform tracks this rapidly evolving pipeline in real time.
Seven Distinct Modalities Targeting the CD39/CD73/Adenosine Axis
From monoclonal antibodies to engineered cell therapies, the retrieved dataset spanning 2012–2023 reveals a rapidly maturing pipeline with active clinical translation signals.
Anti-CD73 Monoclonal Antibodies
Anti-CD73 mAbs represent the most extensively characterized modality in the retrieved dataset. MEDI9447 (oleclumab), a fully human mAb from MedImmune/AstraZeneca, is described as undergoing Phase I clinical trials. Retrieved results from QIMR Berghofer highlight that anti-CD73 mAbs exert distinct mechanisms for control of solid tumors (enzymatic blockade) versus metastases (Fc receptor engagement/ADCC), with mAb epitope and Fc configuration determining mechanistic outcome.
Phase I — MEDI9447 (oleclumab)Anti-CD39 Monoclonal Antibodies
Two distinct mechanisms are described: enzymatic blockade (preserving immunostimulatory ATP) and ADCC-mediated depletion of CD39-expressing suppressive cells. EpimAb Biotherapeutics developed EMB04, a fully humanized anti-CD39 mAb blocking both membrane-associated and soluble CD39 ATPase activity. Tizona Therapeutics engineered a fully human anti-CD39 antibody operating via an uncompetitive allosteric mechanism to inhibit NTPDase1 in the TME.
Preclinical to Early Clinical (IND-enabling)A2A Receptor Small Molecule Antagonists
Multiple distinct compounds are at different clinical stages. DZD2269 (Dizal Pharmaceuticals) is reported as a potent and selective A2AR antagonist designed to maintain full inhibitory activity at the high adenosine concentrations found in the TME—a critical distinction from earlier-generation compounds. PBF-509 (NIR178) restores TIL activity in NSCLC patient samples. Johns Hopkins positions A2AR antagonists as the "next generation checkpoint blockade."
Phase I/II — Multiple CompoundsAntisense Oligonucleotides (ASOs)
Locked nucleic acid (LNA)-modified ASOs with specificity for human and mouse CD39 achieve efficient mRNA and protein-level knockdown in cancer cell lines and primary human T cells without requiring transfection reagents, enabling direct in vivo applicability. Knockdown improves anti-tumor T cell immunity by shifting the ATP/adenosine balance in the TME. This modality was described in a 2019 paper from Medical Oncology.
Preclinical — LNA-modified ASOsEngineered CAR-NK and CAR-T Cell Therapies
Two complementary approaches: (1) NK cells co-expressing anti-CD73 single-chain antibody fragments that block CD73 enzymatic activity while directing NK-cell killing of CD73-overexpressing tumor cells (Purdue University/Rutgers); (2) CRISPR-based knockout of A2AR in human CAR-T cells to prevent adenosine-induced impairment in solid tumor xenograft models (Beijing Cord Blood Bank). In vivo efficacy demonstrated in NSCLC models using piggyBac transposon-engineered NKG2D.CAR-NK cells.
Preclinical — In Vivo ValidationLipid Nanoparticle–Mediated siRNA Delivery
A targeted nanomedicine approach using lipid nanoparticles (LNPs) for delivery of A2AR-specific siRNA into memory T cells in HNSCC is described by University of Cincinnati. This approach rescues adenosine-impaired chemotaxis of CD8+ T cells without requiring systemic A2AR blockade, potentially reducing off-target toxicity compared to systemic small molecule approaches.
Preclinical — HNSCC ModelAdenosine Pathway Pipeline: Development Stage and Combination Evidence
Key data signals extracted from patent filings and academic literature spanning 2012–2023, synthesized via PatSnap Eureka innovation intelligence.
Therapeutic Modalities by Development Stage
A2AR antagonists and anti-CD73 mAbs are the most clinically advanced, with approximately 50 Phase I/II trials cited in a 2023 review. Engineered cell therapies and ASOs remain preclinical.
Combination Strategy Evidence Signals (2012–2023)
CD39/CD73 + PD-1/PD-L1 or CTLA-4 blockade is the most recurrent combination theme, with synergistic improvement demonstrated across multiple solid tumor preclinical models.
Key Targets: Mechanistic Findings Across CD73, CD39, A2AR, A2BR, and CD38
Retrieved results reveal distinct mechanistic roles and resistance nodes across the adenosine axis targets, with implications for therapeutic design and patient stratification.
| Target | Key Mechanistic Finding | Tumor Types | Resistance / Complexity | Stage Signal |
|---|---|---|---|---|
| CD73 (NT5E) | Rate-limiting pacemaker enzyme for extracellular adenosine. In PDAC, CD73 is among top 10% overexpressed genes in ductal-origin tumors. CD73 knockdown ablates in vivo tumor growth and decreases MDSC infiltration via GM-CSF suppression. | PDAC, NSCLC, Colon, Ovarian, Melanoma | Autocrine adenosinergic loop in CD8+ T cells via CD73 during differentiation | Phase I (oleclumab) |
| CD39 (ENTPD1) | Upstream ectonucleotidase; marker of exhausted/regulatory T cells co-expressing PD-1. In AML, CD39 upregulation in chemotherapy-resistant blasts promotes mitochondrial reprogramming via cAMP signaling, conferring cytarabine resistance. In HGSOC, CD39+CD73+ co-expression correlates with worse prognosis across ~1,200 patients. | Melanoma, PDAC, AML, Ovarian (HGSOC), HNSCC | CD38-independent alternative axis bypasses CD39 blockade | Early Clinical |
| A2AR (ADORA2A) | Primary high-affinity transducer of adenosine immunosuppression on CD8+ T cells and NK cells. Adenosine impairs both cytokine production and cytotoxic capacity, and reduces metabolic fitness (Seahorse assay). Prior-generation A2AR antagonists lose potency at high TME adenosine concentrations. | NSCLC, Gastric, Renal, Melanoma | TME adenosine concentration undermines earlier antagonist potency | Phase I/II (DZD2269, PBF-509) |
Monitor CD39/CD73 Biomarker Patent Filings in Real Time
AstraZeneca ACPP splice variant patents and HGSOC prognostic data signal active patient selection IP development
Key Players and Strategic Implications Across the Adenosine Axis Pipeline
Innovation activity in this dataset is predominantly literature-driven (academic), with a smaller but strategically significant patent component from commercial biopharmaceutical entities including AstraZeneca, Corvus Pharmaceuticals, EpimAb, and Dizal.
A2AR Antagonist Potency Under TME Conditions Is the Key Design Parameter
The retrieved dataset strongly signals that A2AR antagonists and anti-CD73 mAbs are the most clinically advanced modalities, with approximately 50 Phase I/II trials cited in 2023. However, limited clinical benefit from early-generation A2AR antagonists suggests potency under TME conditions (high adenosine) is a critical design parameter. Next-generation agents like DZD2269 that maintain activity at TME-level adenosine concentrations may represent a differentiated commercial opportunity.
CD38 and A2BR Represent Insufficiently Exploited Resistance Nodes
A2BR and the alternative CD38/CD203a/CD73 axis represent insufficiently exploited resistance nodes. Programs targeting only CD73 or A2AR may face incomplete pathway blockade in tumors with high CD38 expression or where CD39-independent adenosine generation predominates, suggesting these as rational combination or backup targets for pipeline expansion.
Patient Selection Biomarker IP Is an Active Strategic Area
Patient selection biomarker development (AstraZeneca ACPP splice variant patents; HGSOC CD39/CD73 co-expression prognostic data across ~1,200 patients) is an active IP area that will likely define which patient populations advance into registrational trials. IP strategists should monitor biomarker companion diagnostic filings alongside therapeutic compound patents. PatSnap's IP analytics platform enables real-time biomarker patent monitoring.
Engineered Cell Platforms Signal Near-Term Licensing Opportunity
Engineered NK and T cell platforms co-expressing adenosine axis–blocking moieties represent an emerging, academically-led frontier with clear translational rationale. Commercial licensing or co-development partnerships with CAR-NK/CAR-T platform companies may be a near-term opportunity as these move from in vivo proof-of-concept toward IND-enabling studies. Combination strategies across adenosine + PD-1/PD-L1, TIM3, CDK4/6 inhibitors, and radiotherapy are consistently supported in preclinical evidence.
From Preclinical Promise to Phase I/II: Active Clinical Translation Across the Adenosine Axis
Retrieved results contain multiple clinical translation signals of varying evidential strength. The most significant is a 2023 paper from Augusta University stating that approximately 50 ongoing Phase I/II clinical trials targeting the CD73-adenosinergic immune checkpoint are listed on ClinicalTrials.gov, predominantly employing CD73 inhibitors or A2AR antagonists, most in combination with PD-1/PD-L1 blockade.
MedImmune's anti-CD73 mAb MEDI9447 (oleclumab) is explicitly described as "currently undergoing Phase I clinical trials" in the retrieved dataset, with in vivo syngeneic model data supporting its TME-modulating mechanism. Dizal Pharmaceuticals describes DZD2269 as entering early clinical development, with mechanistic rationale addressing the potency limitation of earlier A2AR antagonists in the TME.
A transcriptomic meta-analysis of approximately 1,200 ovarian cancer patients demonstrates that concomitant CD39 and CD73 co-expression correlates with worse prognosis, particularly in the immunoreactive subgroup, providing a clinical rationale for patient stratification. AstraZeneca's filed patents describe ACPP splice variant ratio (ρ) as a predictive metric for clinical outcomes with adenosine signaling inhibitors.
No retrieved results describe Phase III trial data, regulatory approvals, or confirmed clinical efficacy endpoints for any adenosine pathway–targeted agent in solid tumors. Researchers can access comprehensive clinical intelligence via PatSnap's innovation intelligence platform, trusted by leading pharma and biotech organizations. The European Patent Office records also reflect the growing commercial interest in adenosine pathway biomarker patents from AstraZeneca and Corvus Pharmaceuticals.
CD39/CD73 Adenosine Pathway Pipeline — Key Questions Answered
The CD39/CD73/adenosine axis is a critical immunometabolic checkpoint driving immune evasion and resistance to PD-1/PD-L1 and CTLA-4 blockade in solid tumors. Extracellular adenosine suppresses cytotoxic T cell, NK cell, and innate immune functions. The pathway proceeds through sequential enzymatic hydrolysis: extracellular ATP is catabolized first to ADP and AMP by CD39 (ENTPD1/NTPDase1), then to immunosuppressive adenosine by CD73 (NT5E/ecto-5′-nucleotidase). Adenosine signals through G protein–coupled receptors—primarily A2AR—on immune effector cells, potently dampening antitumor responses.
A2AR antagonists and anti-CD73 monoclonal antibodies are the most clinically advanced modalities, with approximately 50 Phase I/II trials cited in a 2023 review from Augusta University. MedImmune's anti-CD73 mAb MEDI9447 (oleclumab) is explicitly described as undergoing Phase I clinical trials. Multiple A2AR antagonist compounds including PBF-509 (NIR178) and DZD2269 are in Phase I/II development. No Phase III trial data or regulatory approvals have been reported for any adenosine pathway–targeted agent in solid tumors.
A critical mechanistic finding from Dizal Pharmaceuticals describes how prior-generation A2AR antagonists lose potency at the high adenosine concentrations present in the tumor microenvironment (TME), potentially explaining limited clinical efficacy in early trials. This motivated the development of DZD2269, which maintains full inhibitory activity at the high adenosine concentrations found in the TME—a critical distinction from earlier-generation compounds.
Retrieved results from University of Torino identify a CD38/CD203a/CD73 pathway, independent of CD39, that produces extracellular adenosine from NAD+ in human T lymphocytes and melanoma cells. CD38 expression is increased in hematologic and solid tumors and cooperates with CD39/CD73. In melanoma, all tested primary cell lines expressed CD38, CD39, CD73, and CD203a/PC-1, each contributing to T cell proliferation suppression. This alternative axis represents a potential mechanism of resistance to CD39-targeted therapies.
Multiple combination strategies are supported by preclinical evidence: CD39/CD73 pathway inhibition combined with PD-1/PD-L1 or CTLA-4 blockade is the most recurrent theme, with synergistic improvement in antitumor immunity demonstrated in preclinical models. Dual A2AR and TIM3 blockade produces synergistic improvement in anti-tumor immunity in murine renal carcinoma models. Anti-CD73 blockade combined with radiotherapy enhances both local and abscopal immune responses in murine rectal cancer models. A CD73 inhibitor combined with CDK4/6 inhibitor shows additive effect in colorectal cancer.
AstraZeneca holds multiple patent filings covering biomarker-based patient selection for adenosine signaling inhibitor therapy using ACPP transmembrane splice variant expression ratios as a predictive metric correlated with clinical outcome. A transcriptomic meta-analysis of approximately 1,200 ovarian cancer patients demonstrates that concomitant CD39 and CD73 co-expression correlates with worse prognosis, particularly in the immunoreactive subgroup, providing a clinical rationale for patient stratification.
Still have questions? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About This PathwayMap the Full CD39/CD73 Adenosine Axis Pipeline—Patents, Papers, and Clinical Signals in One Platform
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D in immuno-oncology and beyond.
References
- Targeting adenosine for cancer immunotherapy — Bloomberg-Kimmel Institute for Cancer Immunotherapy / Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 2018 [Paper]
- Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy — Augusta University Medical College of Georgia, 2023 [Paper]
- Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors — Purdue University, 2022 [Paper]
- Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function — Lausanne University Hospital (CHUV), 2019 [Paper]
- On the mechanism of anti-CD39 immune checkpoint therapy — Centre Hospitalier de l'Université de Montréal, 2020 [Paper]
- Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells — Ludwig Institute for Cancer Research Lausanne, 2019 [Paper]
- Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity — Medical Oncology, 2019 [Paper]
- Targeting CD73 in the tumor microenvironment with MEDI9447 — MedImmune LLC, 2016 [Paper]
- Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases — QIMR Berghofer Medical Research Institute, 2017 [Paper]
- Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist — Dizal Pharmaceuticals, 2022 [Paper]
- A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment — Ponce Health Sciences University, 2017 [Paper]
- A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy — Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, 2015 [Paper]
- A humanized monoclonal antibody targeting CD39 with novel mechanism for cancer treatment — EpimAb Biotherapeutics Inc., 2021 [Paper]
- Fully human anti-CD39 antibody potently inhibits ATPase activity in cancer cells via uncompetitive allosteric mechanism — Tizona Therapeutics / University of Turku, 2020 [Paper]
- Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells — Purdue University, 2018 [Paper]
- Improving the anti-solid tumor efficacy of CAR-T cells by inhibiting adenosine signaling pathway — Beijing Cord Blood Bank, 2020 [Paper]
- Targeted knockdown of the adenosine A2A receptor by lipid NPs rescues the chemotaxis of head and neck cancer memory T cells — University of Cincinnati College of Medicine, 2021 [Paper]
- Adenosine pathway inhibitors for cancer treatment — Corvus Pharmaceuticals Inc., 2020 [Patent]
- Selecting patients for therapy with adenosine signaling inhibitors — AstraZeneca AB, 2020 [Patent]
- Glycoengineered anti-CD39 promotes anticancer responses by depleting suppressive cells and inhibiting angiogenesis in tumor models — Shandong Provincial Hospital / Shandong First Medical University, 2022 [Paper]
- ClinicalTrials.gov — CD73 and A2AR Antagonist Trial Registry — U.S. National Library of Medicine [Database]
- National Institutes of Health / PubMed — Adenosine Immunotherapy Literature — NIH [Database]
- European Patent Office — Adenosine Pathway Patent Filings — EPO [Database]
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only. It should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.